Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023
May 08, 2023 07:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics' product REBYOTA™ was approved by the...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 03, 2023 05:20 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, med säte i Stockholm, kallar till årsstämma den 8 maj 2023 kl. 15.00 på Westmanska Palatset, konferensrum Bryggarkungen, Holländargatan 17,...
Notice of Annual General Meeting of Infant Bacterial Therapeutics
April 03, 2023 05:20 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on May 8, 2023 at 15.00 CEST at Westmanska...
Infant Bacterial Therapeutics publicerar årsredovisning för 2022
March 22, 2023 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2022. Årsredovisningen finns tillgänglig på IBTs hemsida, www.ibtherapeutics.com under avsnittet...
Infant Bacterial Therapeutics publishes Annual Report for 2022
March 22, 2023 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022. The report is available on IBT´s website, ibtherapeutics.com under the section Ïnvestors & Media – Financial...
Infant Bacterial Therapeutics (IBT) öppnar en sista kohort vilket påskyndar rekryteringen av patienter
March 22, 2023 05:31 ET
|
Infant Bacterial Therapeutics AB
IBT är glada att kunna meddela dagens öppning av den ytterligare kohorten, efter att ha inkluderat 1400 för tidigt födda barn av det totala rekryteringsmålet på 2158. Fram tills nu, och i enlighet men...
Infant Bacterial Therapeutics’ (IBT) opening of a final infant cohort will accelerate patient recruitment
March 22, 2023 05:31 ET
|
Infant Bacterial Therapeutics AB
IBT is pleased to announce today's opening of the additional cohort, having included 1,400 premature infants of the total 2,158 recruitment target. Up until now, and per the protocol agreed with...
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 15, 2023 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product...
7MM CAEL-101 Market Study 2022: A Fibril-reactive Monoclonal Antibody (mAb) - Emerging Drug Insights and Market Forecasts 2019-2022 & 2023-2032
February 15, 2023 07:53 ET
|
Research and Markets
Dublin, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The "CAEL-101 Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering."CAEL-101 Emerging Drug...
Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari – 31 december 2022
February 10, 2023 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Under de sista tre månaderna av 2022 var rekryteringen av prematura spädbarn till vår omfattande fas 3 studie betydligt bättre än vad den var under motsvarande period de föregående...